Patents Assigned to Mochida Pharmaceutical Co., Ltd.
-
Patent number: 11969437Abstract: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.Type: GrantFiled: March 6, 2018Date of Patent: April 30, 2024Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shuichi Endo, Motoi Nakahara
-
Publication number: 20240132854Abstract: There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic ? cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.Type: ApplicationFiled: December 27, 2021Publication date: April 25, 2024Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Naoto TSUDA, Tsutomu SATOH, Tomohiro NARUMI, Shingo SATO
-
Patent number: 11932708Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.Type: GrantFiled: December 11, 2020Date of Patent: March 19, 2024Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji Furusako, Tomohiro Narumi, Tsutomu Satoh
-
Patent number: 11911480Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: GrantFiled: July 17, 2020Date of Patent: February 27, 2024Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata
-
Patent number: 11890145Abstract: An adhesion-preventing material having a high adhesion-preventing effect has been demanded. An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.Type: GrantFiled: August 26, 2022Date of Patent: February 6, 2024Assignees: The University of Tokyo, Mochida Pharmaceutical Co., Ltd.Inventors: Taichi Ito, Seiichi Ohta, Norihiro Kokudo, Mitsuko Isaji, Satoshi Shimizu
-
Publication number: 20230293782Abstract: A material for preventing adhesion having a high adhesion preventing effect has been desired. Provided is a sheet-like material for preventing adhesion which contains alginate, at least a portion of which is crosslinked with a curing agent, the material for preventing adhesion satisfying (1) and (2) when a dissolution test is performed in which a sample cut into a substantial circle having a diameter of 8 mm is left to stand, via a mesh, on agar of a petri dish to which a physiological saline solution is added substantially to a top surface of the agar, the petri dish is shaken at an amplitude of 25 mm and 40 shakes/min., and the weight of the sample is measured at least one arbitrary point in time. (1) The time required for the weight of the sample to be less than 0.01 g is 5-36 hours from a start of the test, and (2) the time required for the weight of the sample to reach the maximum weight is 10 hours or less from the start of the test.Type: ApplicationFiled: July 30, 2021Publication date: September 21, 2023Applicants: Mochida Pharmaceutical Co., Ltd., The University of TokyoInventors: Taichi ITO, Seiichi OHTA, Kiyoshi HASEGAWA, Mitsuko ISAJI, Daichi TANAKA
-
Publication number: 20230285577Abstract: To provide a novel polysaccharide derivative which can be used to form a conjugate with a drug and can be used as a medical material, and a polysaccharide derivative-drug conjugate which uses the same. A polysaccharide derivative obtained by introducing a group represented by formula (A) to a polysaccharide which is acidic, basic or both, and a polysaccharide derivative-drug conjugate of said polysaccharide derivative and a drug.Type: ApplicationFiled: August 10, 2021Publication date: September 14, 2023Applicants: THE UNIVERSITY OF TOKYO, MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Taichi ITO, Seiichi OHTA, Pan QI, Arvind Kumar Singh CHANDEL, Mitsuko ISAJI
-
Publication number: 20230210777Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shuichi ENDO, Naoya YOSHIOKA
-
Patent number: 11685788Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: GrantFiled: May 1, 2020Date of Patent: June 27, 2023Assignee: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Publication number: 20230190943Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.Type: ApplicationFiled: February 2, 2023Publication date: June 22, 2023Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Isao SAKURADA
-
Patent number: 11648229Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.Type: GrantFiled: October 21, 2020Date of Patent: May 16, 2023Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
-
Publication number: 20230145308Abstract: An adhesion-preventing material having a high adhesion-preventing effect has been demanded. An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.Type: ApplicationFiled: August 26, 2022Publication date: May 11, 2023Applicants: Mochida Pharmaceutical Co., Ltd., The University of TokyoInventors: Taichi ITO, Seiichi OHTA, Norihiro KOKUDO, Mitsuko ISAJI, Satoshi SHIMIZU
-
Publication number: 20230080690Abstract: Provided is a composition for treating cartilage injury lesion that is combined with a concentrated bone marrow aspirate and applied to a cartilage injury lesion, that has flowability when applied to the cartilage injury lesion, and that contains a monovalent metal salt of alginic acid. Thereby, a novel composition for treating cartilage injury lesion that can be used to restore and/or regenerate cartilage tissue is provided.Type: ApplicationFiled: January 15, 2021Publication date: March 16, 2023Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., Ltd.Inventors: Norimasa IWASAKI, Tomohiro ONODERA, Atsushi URITA, Ryo JO
-
Publication number: 20230045844Abstract: Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.Type: ApplicationFiled: January 13, 2021Publication date: February 16, 2023Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Tomokazu TAKAI, Hitoshi MIZUNO, Akira TAKAHASHI, Toshiya ENDO, Shinichi SAKAUE, Norimasa IWASAKI, Tomohiro ONODERA, Koji IWASAKI
-
Publication number: 20230041137Abstract: A retractor is provided that can form a joint cavity internal space for a field of view for an endoscope and practice of a treatment in a state where a wound area is spread. A retractor includes first arm portions 2 and 3 and a second arm portion 4 positioned between the first arm portions 2 and 3. The first arm portions 2 and 3 include first claw portions 12 and 13 to be hung on a wound area entrance edge. The second arm portion 4 includes a second claw portion 14 to be hung on the wound area entrance edge. When the first arm portions 2 and 3 and the second arm portion 4 are in a closed state, the first claw portions 12 and 13 and the second claw portion 14 overlap with each other.Type: ApplicationFiled: January 13, 2021Publication date: February 9, 2023Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Hitoshi MIZUNO, Kuniyoshi MASUDA, Masahiko KATAYAMA, Tomokazu TAKAI, Toshiya ENDO, Norimasa IWASAKI, Tomohiro ONODERA, Koji IWASAKI
-
Publication number: 20230035986Abstract: Provided are novel alginic acid derivatives and a novel crosslinked alginic acid. The alginic acid derivatives are represented by formula (I) and formula (II). The novel crosslinked alginic acid obtained by Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II).Type: ApplicationFiled: June 16, 2022Publication date: February 2, 2023Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Tsutomu SATOH, Tomohiro NARUMI
-
Publication number: 20220409773Abstract: Provided is a transplantation device comprising a hydrogel in which insulin-secreting cells or pancreatic islets are enclosed, wherein the hydrogel is prepared by gelatinizing an alginic acid derivative by a chemical crosslinkage. Thus, a novel transplantation device is provided.Type: ApplicationFiled: June 26, 2020Publication date: December 29, 2022Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINEInventors: Masayuki SHIMODA, Kumiko AJIMA, Shoji FURUSAKO
-
Publication number: 20220396643Abstract: Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked alginic acid, crosslinked alginic acid structure, etc., are provided.Type: ApplicationFiled: September 24, 2020Publication date: December 15, 2022Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Tomohiro NARUMI, Tsutomu SATOH
-
Publication number: 20220370404Abstract: This disclosure provides a means for treating dry eye. This disclosure can provide: a composition for use in treating dry eye; and a use thereof. The composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof. This disclosure can provide: a composition for treating dry eye; and a use thereof. The composition includes a Vi/Vc zone inhibitor.Type: ApplicationFiled: October 2, 2020Publication date: November 24, 2022Applicants: SENJU PHARMACEUTICAL CO., LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Takeshi TARUI, Shinya KOBAYASHI
-
Publication number: 20220348552Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.Type: ApplicationFiled: April 1, 2022Publication date: November 3, 2022Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE, Tsutomu SATOH